-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter

Wall Street analysts expect Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) to announce earnings per share (EPS) of ($0.04) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Intellipharmaceutics International’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at $0.03. Intellipharmaceutics International reported earnings per share of ($0.14) during the same quarter last year, which suggests a positive year-over-year growth rate of 71.4%. The business is expected to issue its next quarterly earnings results on Friday, February 9th.

According to Zacks, analysts expect that Intellipharmaceutics International will report full-year earnings of ($0.21) per share for the current fiscal year, with EPS estimates ranging from ($0.31) to ($0.11). For the next fiscal year, analysts forecast that the firm will report earnings of $0.10 per share, with EPS estimates ranging from ($0.32) to $0.51. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Intellipharmaceutics International.

Several equities analysts have recently issued reports on IPCI shares. Maxim Group lowered their price target on Intellipharmaceutics International from $6.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, July 27th. Mackie raised Intellipharmaceutics International to a “hold” rating and raised their price objective for the stock from $1.00 to $3.10 in a research note on Tuesday, September 26th. Zacks Investment Research raised Intellipharmaceutics International from a “sell” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, ValuEngine lowered Intellipharmaceutics International from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $2.37.

ILLEGAL ACTIVITY NOTICE: “-$0.04 Earnings Per Share Expected for Intellipharmaceutics International Inc. (IPCI) This Quarter” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://sportsperspectives.com/2017/11/20/0-04-earnings-per-share-expected-for-intellipharmaceutics-international-inc-ipci-this-quarter-2.html.

An institutional investor recently raised its position in Intellipharmaceutics International stock. Advisor Group Inc. lifted its stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) by 57.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 47,409 shares of the company’s stock after acquiring an additional 17,342 shares during the quarter. Advisor Group Inc. owned 0.16% of Intellipharmaceutics International worth $100,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 3.57% of the company’s stock.

Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded down $0.03 during mid-day trading on Monday, hitting $0.88. The stock had a trading volume of 239,695 shares, compared to its average volume of 305,691. Intellipharmaceutics International has a one year low of $0.81 and a one year high of $3.35.

Intellipharmaceutics International Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Get a free copy of the Zacks research report on Intellipharmaceutics International (IPCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply